6533b85bfe1ef96bd12baa0b

RESEARCH PRODUCT

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Alessia CimadamorePorta CamilloGiacomo CartenìPaolo Andrea ZucaliCinzia OrtegaRoberto IacovelliMatteo SantoniDaniele SantiniAlessandra MoscaErin PierceMarc R. MatranaElena VerzoniOrazio CaffoMichele MilellaRodolfo MontironiSebastiano ButiJeffrey GrahamSara MerlerFrancesco CarrozzaSergio BracardaMarina ScarpelliUmberto BassoFrancesco MassariFrancesco PivaLiang ChengVittorio PaolucciAngelo MartignettiFranco MorelliCristina MasiniFabio CalabròGiuseppe FornariniSarah ScagliariniLorena IncorvaiaNuno VauMimma RizzoFrancesco AtzoriAlain GelibterRiccardo RicottaAntonio Lopez-beltranMaria Giuseppa VitaleUgo De GiorgiSimon J. CrabbGiulia SorgentoniPierangela SepeLuca GalliGiuseppe ProcopioDaniel Y. HengAlessandro ContiNicola Battelli

subject

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyrenal cell carcinomaCabozantinibPrognosiContext (language use)urologic and male genital diseaseslcsh:RC254-282ArticlePazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineProgression-free survivalCabozantinib; Nivolumab; Prognosis; Real-world data; Renal cell carcinoma; Targeted therapynivolumabreal-world databusiness.industrySunitinibRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyAxitinib030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisprognosisbusinessmedicine.drug

description

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan&ndash

yearjournalcountryeditionlanguage
2019-12-30Cancers
10.3390/cancers12010084http://dx.doi.org/10.3390/cancers12010084